Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02924324 · ClinicalTrials.gov registry record · NA
Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT02924324: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02924324 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02924324, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone marrow procedures. The addition of this medicine, called ropivacaine, is the experimental part of this study. This is the first time ropivacaine will be directly injected into the bone marrow site at MSKCC Pediatrics.
Interventions
- DRUG ropivacaine
- DEVICE propofol
- BEHAVIORAL Wong-Baker FACES® Pain Rating Scale
- BEHAVIORAL Post-procedural quality of life (QOL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02924324
The ClinicalTrials.gov registry entry for NCT02924324 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ropivacaine is the first listed.
NCT02924324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02924324 about?
NCT02924324 is a clinical study titled "Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients". The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone marrow procedures. The addition of this medicine, called ropivacaine, is th...
What is the current status of trial NCT02924324?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2016-10. Estimated completion is 2019-11.
What interventions are being tested in trial NCT02924324?
The interventions under investigation include: ropivacaine (DRUG), propofol (DEVICE), Wong-Baker FACES® Pain Rating Scale (BEHAVIORAL), Post-procedural quality of life (QOL) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02924324?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.